ArticleAnnals of surgical oncology2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the feasibility and clinical outcomes of neoadjuvant triplet therapy with gemcitabine, cisplatin, and nab-paclitaxel (GAP) for patients with borderline resectable cholangiocarcinoma (CCA). Given the surgical complexity associated with borderline resectable disease, the study sought to explore whether GAP could serve as a suitable neoadjuvant regimen to enable conversion to resection and improve prognosis in this high-risk setting.
methodsThe study enrolled patients with borderline resectable CCA receiving neoadjuvant GAP between July 2019 and February 2024. Rates of conversion to surgery, perioperative safety, radiologic and pathologic treatment responses, and survival outcomes were evaluated.
resultsOf 108 screened patients, 71 (65.7%) with anatomically or biologically borderline resectable CCA received neoadjuvant GAP therapy, 34 (47.9%) of whom underwent curative-intent resection. Among the resected patients, 50.0% underwent extended hepatectomy, 32.4% underwent extrahepatic bile duct resection, and 14.7% underwent vascular reconstruction. Radiologic evaluation showed an overall response rate of 50.0% and a disease control rate of 94.1%. Grade ≥3 treatment-related adverse events were observed in 21% of the patients, primarily involving hematologic toxicities. Major postoperative complications occurred for 35.3% of the patients, with no 90-day mortalities. The resected patients demonstrated significantly better overall survival (OS) than the non-resected patients (median OS, 68.7 vs. 24.4 months; p < 0.001).
conclusionNeoadjuvant GAP demonstrated promising efficacy for borderline resectable CCA, with favorable response rates and the potential to facilitate curative-intent resection. However, its use is mitigated by treatment-related toxicity, emphasizing the significance of careful patient selection. Further prospective studies are warranted to validate its role in optimizing surgical and long-term oncologic outcomes.
Indexed as
Identifiers
40760317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.